|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FTO |
Gene summary for FTO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FTO | Gene ID | 79068 |
| Gene name | FTO alpha-ketoglutarate dependent dioxygenase | |
| Gene Alias | ALKBH9 | |
| Cytomap | 16q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | B3KU60 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79068 | FTO | CCI_1 | Human | Cervix | CC | 1.46e-06 | 7.90e-01 | 0.528 |
| 79068 | FTO | CCI_2 | Human | Cervix | CC | 3.07e-02 | 5.72e-01 | 0.5249 |
| 79068 | FTO | CCI_3 | Human | Cervix | CC | 6.36e-12 | 7.49e-01 | 0.516 |
| 79068 | FTO | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.69e-13 | -4.22e-01 | 0.0155 |
| 79068 | FTO | HTA11_696_2000001011 | Human | Colorectum | AD | 3.12e-03 | -2.62e-01 | -0.1464 |
| 79068 | FTO | HTA11_866_2000001011 | Human | Colorectum | AD | 1.92e-04 | -3.28e-01 | -0.1001 |
| 79068 | FTO | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.03e-03 | -6.56e-01 | -0.2061 |
| 79068 | FTO | HTA11_866_3004761011 | Human | Colorectum | AD | 1.26e-05 | -4.47e-01 | 0.096 |
| 79068 | FTO | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.55e-02 | -2.66e-01 | 0.0674 |
| 79068 | FTO | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.67e-09 | -4.28e-01 | 0.294 |
| 79068 | FTO | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.13e-13 | -5.19e-01 | 0.3005 |
| 79068 | FTO | F007 | Human | Colorectum | FAP | 1.68e-03 | -2.24e-01 | 0.1176 |
| 79068 | FTO | A001-C-207 | Human | Colorectum | FAP | 7.55e-06 | -3.41e-01 | 0.1278 |
| 79068 | FTO | A015-C-203 | Human | Colorectum | FAP | 1.26e-39 | -5.08e-01 | -0.1294 |
| 79068 | FTO | A015-C-204 | Human | Colorectum | FAP | 2.92e-11 | -4.19e-01 | -0.0228 |
| 79068 | FTO | A014-C-040 | Human | Colorectum | FAP | 3.24e-05 | -5.00e-01 | -0.1184 |
| 79068 | FTO | A002-C-201 | Human | Colorectum | FAP | 4.55e-19 | -5.12e-01 | 0.0324 |
| 79068 | FTO | A002-C-203 | Human | Colorectum | FAP | 6.87e-05 | -1.40e-01 | 0.2786 |
| 79068 | FTO | A001-C-119 | Human | Colorectum | FAP | 2.38e-08 | -4.95e-01 | -0.1557 |
| 79068 | FTO | A001-C-108 | Human | Colorectum | FAP | 3.83e-26 | -4.26e-01 | -0.0272 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
| GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
| GO:003133110 | Cervix | CC | positive regulation of cellular catabolic process | 91/2311 | 427/18723 | 9.64e-08 | 5.25e-06 | 91 |
| GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
| GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
| GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
| GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
| GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
| GO:00610139 | Cervix | CC | regulation of mRNA catabolic process | 38/2311 | 166/18723 | 1.07e-04 | 1.36e-03 | 38 |
| GO:19033136 | Cervix | CC | positive regulation of mRNA metabolic process | 29/2311 | 118/18723 | 1.86e-04 | 2.18e-03 | 29 |
| GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 |
| GO:00346559 | Cervix | CC | nucleobase-containing compound catabolic process | 74/2311 | 407/18723 | 3.77e-04 | 3.88e-03 | 74 |
| GO:00434889 | Cervix | CC | regulation of mRNA stability | 35/2311 | 158/18723 | 3.80e-04 | 3.89e-03 | 35 |
| GO:00611576 | Cervix | CC | mRNA destabilization | 22/2311 | 84/18723 | 4.18e-04 | 4.23e-03 | 22 |
| GO:00610146 | Cervix | CC | positive regulation of mRNA catabolic process | 22/2311 | 87/18723 | 7.03e-04 | 6.40e-03 | 22 |
| GO:0045598 | Cervix | CC | regulation of fat cell differentiation | 31/2311 | 139/18723 | 7.06e-04 | 6.41e-03 | 31 |
| GO:00486386 | Cervix | CC | regulation of developmental growth | 61/2311 | 330/18723 | 7.69e-04 | 6.85e-03 | 61 |
| GO:00434879 | Cervix | CC | regulation of RNA stability | 36/2311 | 170/18723 | 7.72e-04 | 6.86e-03 | 36 |
| GO:00442709 | Cervix | CC | cellular nitrogen compound catabolic process | 79/2311 | 451/18723 | 7.80e-04 | 6.91e-03 | 79 |
| GO:00507796 | Cervix | CC | RNA destabilization | 22/2311 | 88/18723 | 8.30e-04 | 7.23e-03 | 22 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FTO | SNV | Missense_Mutation | rs577569584 | c.559G>A | p.Gly187Arg | p.G187R | Q9C0B1 | protein_coding | tolerated(0.52) | benign(0.033) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| FTO | SNV | Missense_Mutation | c.1180N>A | p.Asp394Asn | p.D394N | Q9C0B1 | protein_coding | tolerated(0.1) | probably_damaging(0.946) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FTO | SNV | Missense_Mutation | novel | c.584N>T | p.Ser195Ile | p.S195I | Q9C0B1 | protein_coding | tolerated(0.07) | possibly_damaging(0.785) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| FTO | SNV | Missense_Mutation | c.574N>C | p.Asp192His | p.D192H | Q9C0B1 | protein_coding | tolerated(0.07) | possibly_damaging(0.77) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| FTO | insertion | Frame_Shift_Ins | novel | c.582_583insTCTGCTCACTCCGGTATCTCGCATCCTCATTGGTA | p.Arg196AlafsTer11 | p.R196Afs*11 | Q9C0B1 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| FTO | deletion | Frame_Shift_Del | novel | c.865delC | p.Leu289PhefsTer68 | p.L289Ffs*68 | Q9C0B1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FTO | SNV | Missense_Mutation | c.1042G>A | p.Asp348Asn | p.D348N | Q9C0B1 | protein_coding | tolerated(0.11) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FTO | SNV | Missense_Mutation | novel | c.1132N>A | p.Trp378Arg | p.W378R | Q9C0B1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| FTO | SNV | Missense_Mutation | c.1180G>A | p.Asp394Asn | p.D394N | Q9C0B1 | protein_coding | tolerated(0.1) | probably_damaging(0.946) | TCGA-EK-A2RM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FTO | SNV | Missense_Mutation | rs577569584 | c.559N>A | p.Gly187Arg | p.G187R | Q9C0B1 | protein_coding | tolerated(0.52) | benign(0.033) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 79068 | FTO | ENZYME | interferon alfa-2b, recombinant | 25367448 | ||
| 79068 | FTO | ENZYME | mercaptopurine | MERCAPTOPURINE | 27558924 | |
| 79068 | FTO | ENZYME | azathioprine | AZATHIOPRINE | 27558924 | |
| 79068 | FTO | ENZYME | interferon alfa-2a, recombinant | 25367448 | ||
| 79068 | FTO | ENZYME | ribavirin | RIBAVIRIN | 25367448 | |
| 79068 | FTO | ENZYME | atenolol | ATENOLOL | ||
| 79068 | FTO | ENZYME | ethanol | ALCOHOL | 32451486 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |